Drawing for QIAGEN PARTNER

USPTO serial 79409549

QIAGEN PARTNER

Reviewed by CopyMark Law Group

Reg. 7979833Status 700Registered
Filing date
Status date
Registration date
Oct 14, 2025
Examiner
CASTRO, GIANCARLO
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with QIAGEN PARTNER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

G MATHEW LOMBARD

G MATHEW LOMBARD LOMBARD & GELIEBTER LLP1325 AVENUE OF THE AMERICAS28 FLOORNEW YORK, NY 10019

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, in particular reagents, enzymes and buffer solutions for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; kits containing preparations for medical and veterinary diagnostic purposes, in particular for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; chemical reagents for medical purposes; cartridges containing medical diagnostic reagents for use in Polymerase Chain Reaction (PCR) or digital Polymerase Chain Reaction (PCR) instruments; medical diagnostic assays for testing of body samples, including bodily fluids and tissue in the detection, monitoring, and prediction of disease or other conditions, disease states, hormone level, drug level, drug response, organ function effectiveness, and clinical response; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics.ACTIVE—
010Apparatus for medical and veterinary diagnostic analysis and determination of medical and veterinary conditions, namely DNA and RNA testing apparatus; Medical and veterinary equipment for diagnostic purposes; clinical medical laboratory apparatus and analytical instruments, namely digital Polymerase Chain Reaction (d PCR) instruments for use in in-vitro and in-vivo diagnostics; medical devices for detection of infectious disease, namely, digital polymerase chain reaction (dPCR) platforms; medical devices for use in pre-natal screenings, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in detecting, diagnosing and treating cancer and infectious disease, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in pre-natal screenings, namely, digital polymerase chain reaction (PCR) platform; medical devices, namely, instruments for use in measuring and quantifying copy number of DNA for medical diagnostic purposes, namely, digital polymerase chain reaction (dPCR) platform; microfluidic plates for use as medical apparatus.ACTIVE—
044Testing services, namely, quantifying DNA and RNA for medical, diagnostic and treatment purposes; rental of digital Polymerase Chain Reaction (PCR) apparatus; RNA or DNA analysis for cancer diagnosis and prognosis; Medical services, in particular medical analysis in connection with the treatment of individuals; providing information in the fields of medicine, veterinary medicine and pharmaceuticals; health centers, namely, genetic centers providing medical diagnostic, preventive and curative therapy services for genetic disorders, cancer treatment centers, rare disease treatment centers, children's hospitals and women's hospital; medical clinics; gene therapy services in the field of oncology, infertility, prenatal diagnostics, carrier testing, and genetically inherited diseases; medical laboratory services for the analysis of samples taken from patients.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 7, 2026FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 30, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 23, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 23, 2026FIMPFINAL DISPOSITION PROCESSED—
Apr 13, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 13, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 14, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 14, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 14, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 26, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 26, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 20, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 23, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 16, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 16, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 16, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 29, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 11, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 11, 2025RFRRREFUSAL PROCESSED BY MPU—
Jan 23, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 22, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2025DOCKASSIGNED TO EXAMINER—
Nov 17, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 17, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 14, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance